Comments
Novartis on Friday said it had received European Union approval for its Luxturna gene therapy to restore sight to people with a rare retinal disease.
Luxturna is a one-time treatment for children and adults who have suffered impaired vision from an early age due to mutations in both copies of the RPE65 gene. Such mutations, which can lead to blindness, affect roughly 1 in 200,000 people, according to Novartis.
The authorisation is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway, Novartis said. Luxturna was developed and is commercialized in the United States by Spark Therapeutics.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.